Conatus Pharmaceuticals (CNAT) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Conatus Pharmaceuticals (NASDAQ:CNAT) issued its earnings results on Wednesday. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05, Bloomberg Earnings reports. The business had revenue of $8.77 million for the quarter, compared to the consensus estimate of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%.

Shares of Conatus Pharmaceuticals traded up $0.04, hitting $4.03, during midday trading on Thursday, according to MarketBeat Ratings. The company had a trading volume of 358,100 shares, compared to its average volume of 607,459. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.57. Conatus Pharmaceuticals has a twelve month low of $3.22 and a twelve month high of $7.95. The stock has a market capitalization of $121.76 million, a price-to-earnings ratio of -6.61 and a beta of 1.23.

Several analysts recently commented on CNAT shares. Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, April 5th. HC Wainwright reduced their price objective on shares of Conatus Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, April 5th. SunTrust Banks reduced their price objective on shares of Conatus Pharmaceuticals to $4.30 and set a “buy” rating for the company in a research note on Thursday, April 5th. ValuEngine cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 6th. Finally, Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 10th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $12.14.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Article: Momentum Indicator: Relative Strength Index

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply